Carlos Ávila Nieto
Carlos Ávila graduated in Biochemistry from the University of Seville in 2016, after one year of internship in the Centro Andaluz de Biología del Desarrollo. In 2017 he moved to Barcelona to undertake a MSc in Advanced Immunology from the University of Barcelona - Autonomous University of Barcelona. His MSC thesis, carried out in IrsiCaixa, was focused on the development of an ex vivo cellular model to evaluate shock and kill therapies in HIV patients.
In 2018 he worked in AlbaJuna Therapeutics, SL., a IrsiCaixa spin-off, as a lab technician involved in the production and purification of antibodies. Since 2019 he has been employed as a pre-doctoral researcher in the IrsiCaixa Cell Virology and Immunology group, with Dr Julià Blanco and Dr Jorge Carrillo as his thesis supervisors. His work is focused on the development of a syphilis vaccine based on virus-like particles (VLPs) derived from HIV.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.
The first year of young group of the Spanish immunology society: Progress, challenges, and next steps.
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.
Comparison of Reverse Transcription (RT)-Quantitative PCR and RT-Droplet Digital PCR for Detection of Genomic and Subgenomic SARS-CoV-2 RNA.